Naveen Krishnan (@prince_naveenk) 's Twitter Profile
Naveen Krishnan

@prince_naveenk

Physician turned venture capitalist trying to bring therapies to patients

ID: 762003547512774656

calendar_today06-08-2016 19:12:57

25 Tweet

111 Takipçi

61 Takip Edilen

Bruce Booth (@lifescivc) 's Twitter Profile Photo

The approval of generic active drug combo Relyvrio is a win for advocacy over data; in light of this, the expected pricing >$120,000 seems egregious. ICER value-based pricing suggests that’s 5-10x too high. Violates the social contract IMO: get great data, earn premium pricing

Naveen Krishnan (@prince_naveenk) 's Twitter Profile Photo

We are thrilled to release our official website for Mirae Asset Capital Life Science: lifesci.miraeasset.com Please check it out to find out more about our fund, investment strategy, the types of companies invest in, who we are, and to contact us. David T. Paik, PhD

Naveen Krishnan (@prince_naveenk) 's Twitter Profile Photo

We are proud to announce our launch with our $50M fund dedicated to investment in life science with primary focus in the U.S. Please check out our website lifesci.miraeasset.com and reach out if you are a good fit! David T. Paik, PhD Mirae Asset Capital Life Science businesswire.com/news/home/2024…

Naveen Krishnan (@prince_naveenk) 's Twitter Profile Photo

We are thrilled to lead the $75m Series C in Accent Tx as our first investment for Mirae Asset Capital Life Science and look forward to bringing cancer therapies to patients who need them most! prnewswire.com/news-releases/… Accent Therapeutics, Inc. Mirae Asset Capital Life Science David T. Paik, PhD

Naveen Krishnan (@prince_naveenk) 's Twitter Profile Photo

We are proud to announce more exciting news on our second investment, Vignette Bio, including its merger with TRC 2004 into Candid Therapeutics (candidrx.com) and the Series B financing bringing over $370M into the company! Mirae Asset Capital Life Science businesswire.com/news/home/2024…